- Home
- ZEO vs ENLV Comparison
ZEO vs ENLV Comparison
Compare ZEO & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- ENLV
- Stock Information
- Founded
- ZEO 2005
- ENLV 2005
- Country
- ZEO United States
- ENLV Israel
- Employees
- ZEO N/A
- ENLV N/A
- Industry
- ZEO
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- ENLV Health Care
- Exchange
- ZEO NYSE
- ENLV Nasdaq
- Market Cap
- ZEO 19.5M
- ENLV 20.7M
- IPO Year
- ZEO N/A
- ENLV 1995
- Fundamental
- Price
- ZEO $1.55
- ENLV $0.92
- Analyst Decision
- ZEO
- ENLV Strong Buy
- Analyst Count
- ZEO 0
- ENLV 2
- Target Price
- ZEO N/A
- ENLV $10.00
- AVG Volume (30 Days)
- ZEO 1.2M
- ENLV 62.6K
- Earning Date
- ZEO 05-14-2025
- ENLV 06-13-2025
- Dividend Yield
- ZEO N/A
- ENLV N/A
- EPS Growth
- ZEO N/A
- ENLV N/A
- EPS
- ZEO N/A
- ENLV N/A
- Revenue
- ZEO $77,582,314.00
- ENLV N/A
- Revenue This Year
- ZEO N/A
- ENLV N/A
- Revenue Next Year
- ZEO N/A
- ENLV N/A
- P/E Ratio
- ZEO N/A
- ENLV N/A
- Revenue Growth
- ZEO N/A
- ENLV N/A
- 52 Week Low
- ZEO $1.05
- ENLV $0.81
- 52 Week High
- ZEO $5.25
- ENLV $1.84
- Technical
- Relative Strength Index (RSI)
- ZEO 48.08
- ENLV 44.97
- Support Level
- ZEO $1.49
- ENLV $0.86
- Resistance Level
- ZEO $1.77
- ENLV $0.91
- Average True Range (ATR)
- ZEO 0.25
- ENLV 0.06
- MACD
- ZEO 0.04
- ENLV 0.00
- Stochastic Oscillator
- ZEO 23.65
- ENLV 47.06
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.